<img src="https://crypto.news/app/uploads/2023/11/crypto-news-hologram-artificial-intelligence-blurry-epic-art-background-neon-colors01.webp” />
Disclosure: This article does not represent investment advice. The content and materials appearing on this page are for educational purposes only.
2024 is off to a good start – a great start to what many believe will be a bull market. While some tokens have had a head start, crypto experts anticipate XRP prices to rise. This is due to its disappointing performance in Q4 2023. Meanwhile, traders are bullish on Injective (INJ) and InQubeta (QUBE).
This post will cover the expected XRP price rise and the optimism around Injective and InQubeta.
The InQubeta approach
InQubeta is a low market cap project that has raised over $7.9 million in seed funding.
It sits at the intersection of ai and blockchain, two of the world's most transformative innovations.
Their unique approach will introduce a novel fundraising approach to the ai sector.
InQubeta aims to be a crowdfunding platform for ai startups. Additionally, its nft marketplace will be a hub for ai companies or projects vetted in their early stages.
In the sixth stage of the pre-sale, QUBE is available for $0.01925. Experts say the token could have more advantages once it is launched.
Is the XRP rally coming?
After Ripple and XRP made headlines in mid-2023, prices plummeted.
However, analysts expect prices to recover despite their disappointing performance in the second half of 2023.
Injective ready for profits
Injective was one of the highlights of 2023 after posting strong rallies.
Analysts expect INJ bulls to extend their gains.
Injective is dedicated to finance, driving next generation defi applications where INJ will play a key role.
Conclusion
Analysts expect cryptocurrency prices to rise in 2024. While cryptocurrency experts say XRP will rise, traders are banking on Injective and InQubeta to outperform the market.
Disclosure: This content is provided by a third party. crypto.news does not endorse any products mentioned on this page. Users should conduct their own research before taking any action related to the company.
